Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation

The Rudbeck Laboratory, Uppsala University, Uppsala, Uppsala, Sweden
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K (Impact Factor: 9.38). 01/2008; 21(12):2540-4. DOI: 10.1038/sj.leu.2404828
Source: PubMed
Download full-text


Available from: Ernesto De Meis, Apr 14, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Data hiding procedures embed digital data in a host audio, image or video signal. The embedded data is perceptually and statistically invisible until extracted by the proper algorithm. In this paper we investigate the use of data hiding for media compression. We propose a media compression scheme which applies data hiding procedures to "fold" a media signal into itself. Specifically the media signal to be compressed is split into host and residual parts. The residual part is compressed and embedded into the host part. The host part is compressed with standard compression techniques and transmitted to the decoder. As a result, only part of the original signal is needed to be compressed, and the perceptual quality of the compressed signal is not sacrificed. Bit rate reduction by the proposed method is proportional to the redundancy and irrelevancy remaining in the compressed signal. The proposed scheme works since no current compression schemes can completely remove the redundancy and irrelevancy in a signal.
    Signals, Systems & Computers, 1997. Conference Record of the Thirty-First Asilomar Conference on; 12/1997
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although it is only used to treat a minority of patients with myelodysplastic syndromes, stem cell transplantation (SCT) is the only proven curative treatment for this condition. Because MDS occurs in a population of older adults with significant comorbidities, reduced-intensity conditioning (RIC) regimens have been particularly important in extending safe SCT to the large MDS population over the age of 60 years. Extension of the unrelated donor pool together with the introduction of umbilical cord blood transplants in adults has extended the number of patients with suitable donors. Nevertheless overall mortality from SCT is greater than 50% because of relapse and non-relapse mortality (NRM). New developments to improve outcome include the tailoring of the transplant approach to the individual based on age and comorbidity, and the use of pretransplant chemotherapy to reduce disease bulk prior to transplant, as well as the introduction of post-transplant immunotherapy (pre-emptive donor lymphocyte infusions) and chemotherapy to prevent relapse. Further improvements in transplant outcome await better ways to reconstitute immunity and amplify the graft-versus-leukemia (GVL) effect without causing graft-versus-host disease (GVHD), as well as further extension of the donor pool and exploration of risk-adapted regimens for the population of MDS in their seventh to eighth decade.
    Seminars in Hematology 02/2008; 45(1):49-59. DOI:10.1053/j.seminhematol.2007.10.005 · 2.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Relapse of primary disease and occurrence of new cancers can cause significant morbidity and mortality in recipients of autologous and allogeneic hematopoietic-cell transplantation (HCT). Treatment options for relapse are generally limited and can include disease-specific chemotherapy or targeted therapy. Additional relapse-directed therapies that are available for allogeneic HCT recipients include withdrawal of immunosuppression and donor lymphocyte infusion. Selected patients can be offered a second transplant procedure. Newer strategies to eliminate minimal residual disease and, in allogeneic HCT recipients, to augment the graft-versus-tumor effect are needed for patients who are at high risk for relapse after HCT. Second cancers after HCT include post-transplant lymphoproliferative disorder, hematologic malignancies and new solid cancers. The incidence of second solid cancers continues to rise without a plateau with increasing follow up of HCT survivors. Secondary myelodysplastic syndrome and acute leukemia are almost exclusively seen in autologous HCT recipients while post-transplant lymphoproliferative disorders complicate recipients of allogeneic HCT. Appropriate screening evaluations should be performed in HCT survivors to facilitate early detection and treatment of second cancers.
    Hematology 02/2008; 2008(1):142-9. DOI:10.1182/asheducation-2008.1.142 · 2.86 Impact Factor
Show more